"๐๐ ๐ฐ๐ ๐ญ๐ซ๐๐๐ญ ๐๐ ๐๐ฌ ๐ ๐๐จ๐ฌ๐ญ-๐๐ฎ๐ญ๐ญ๐ข๐ง๐ ๐ญ๐จ๐จ๐ฅ, ๐ฐ๐ ๐ฐ๐ข๐ฅ๐ฅ ๐ ๐๐ญ ๐ ๐๐ก๐๐๐ฉ๐๐ซ ๐ฏ๐๐ซ๐ฌ๐ข๐จ๐ง ๐จ๐ ๐ญ๐ก๐ ๐ฌ๐ฒ๐ฌ๐ญ๐๐ฆ ๐ฐ๐ ๐๐ฅ๐ซ๐๐๐๐ฒ ๐ก๐๐ฏ๐. ๐๐ ๐ฐ๐ ๐ญ๐ซ๐๐๐ญ ๐ข๐ญ ๐๐ฌ ๐๐ง ๐๐ช๐ฎ๐ข๐ญ๐ฒ ๐ญ๐จ๐จ๐ฅ, ๐ฐ๐ ๐ฐ๐ข๐ฅ๐ฅ ๐ ๐๐ญ ๐ฌ๐จ๐ฆ๐๐ญ๐ก๐ข๐ง๐ ๐ ๐๐ง๐ฎ๐ข๐ง๐๐ฅ๐ฒ ๐ง๐๐ฐ."
Us2.ai co-founder Dr. Carolyn Lam in a new Q&A in Med with Cell Press.
๐Read the full Q&A: doi.org/10.1016/j.medj.2026.โฆ
Super excited about this! ๐ฆพ
๐๐ข๐ ๐ง๐๐ฐ๐ฌ! ๐๐ฌ2.๐๐ข ๐๐ง๐ย @CanonMedicalUS ๐ก๐๐ฏ๐ ๐๐ง๐ง๐จ๐ฎ๐ง๐๐๐ ๐ ๐ซ๐๐ฌ๐๐ฅ๐ฅ๐๐ซ ๐ซ๐๐ฅ๐๐ญ๐ข๐จ๐ง๐ฌ๐ก๐ข๐ฉ ๐๐จ๐ซ ๐๐-๐๐ง๐๐๐ฅ๐๐ ๐๐๐ก๐จ๐๐๐ซ๐๐ข๐จ๐ ๐ซ๐๐ฉ๐ก๐ฒ ๐
Through this relationship, Canon Medical Systems USA will offer Us2.ai's cloud-based AI echocardiography software as part of its broader echocardiography portfolio, giving customers additional flexibility to adopt AI within their existing workflows.
For echo labs already using Canon's Aplio i-series, this means a practical path to bringing automated measurements, consistent reporting and AI-driven diagnostic support into daily practice.
We are proud to be working with Canon Medical Systems USA to expand access to AI echo.
๐ Read the full press release: us.medical.canon/news/press-โฆ
31
Dr. Jasper Tromp led an economic evaluation of AI-assisted LVEF assessment in Singapore. ๐๐ก๐ ๐๐จ๐ง๐๐ฅ๐ฎ๐ฌ๐ข๐จ๐ง: ๐๐-๐ฉ๐จ๐ฐ๐๐ซ๐๐ ๐ฉ๐จ๐ข๐ง๐ญ-๐จ๐-๐๐๐ซ๐ ๐ฎ๐ฅ๐ญ๐ซ๐๐ฌ๐จ๐ฎ๐ง๐ ๐ข๐ฌ ๐ง๐จ๐ญ ๐ฃ๐ฎ๐ฌ๐ญ ๐๐ฅ๐ข๐ง๐ข๐๐๐ฅ๐ฅ๐ฒ ๐๐๐๐ฎ๐ซ๐๐ญ๐ โ ๐ข๐ญ'๐ฌ ๐ ๐ฐ๐๐จ๐ฌ๐ญ-๐ฌ๐๐ฏ๐ข๐ง๐ ๐ฐ ๐ฉ๐๐ญ๐ก ๐๐จ๐ซ ๐๐๐ซ๐๐ข๐๐ ๐๐๐ซ๐.
Published in ESC Heart Failure, the study looked at the cost of AI-assisted LVEF assessment using Us2.ai, performed by novices, versus standard sonographer-led echocardiography in Singapore.
Same diagnostic accuracy. Significantly lower cost.
Dr. Tromp, Assistant Professor at the Saw Swee Hock School of Public Health, National University of Singapore, shares what this means for healthcare systems where echocardiographic capacity is limited and heart failure is on the rise.
We are proud to have Us2.ai as the AI echo software featured in this work!
๐ Full study: us2.ai/clinical-evidence/ai-โฆ
๐๐ก๐ข๐ฌ ๐ข๐ฌ ๐๐ฌ2.๐๐ข. ๐๐ก๐จ ๐ฐ๐ ๐๐ซ๐, ๐ฐ๐ก๐ฒ ๐ฐ๐ ๐๐ฎ๐ข๐ฅ๐ญ ๐ข๐ญ, ๐๐ง๐ ๐ฐ๐ก๐๐ญ ๐ข๐ญ ๐ฆ๐๐๐ง๐ฌ ๐๐จ๐ซ ๐ญ๐ก๐ ๐๐ฎ๐ญ๐ฎ๐ซ๐ ๐จ๐ ๐๐๐ก๐จ๐๐๐ซ๐๐ข๐จ๐ ๐ซ๐๐ฉ๐ก๐ฒ.
At the heart of everything we do is a simple mission: make echocardiography analysis more accurate, more efficient and more accessible for clinicians and patients around the world.
"The gain that you get, the reduction of error in reducing variability of day to day measurements doesn't even speak to the other benefits of using an AI echo platform like this, and the efficiency gains in throughput in a lab, is incredibly amazing." โ Dr. Ken Stein
If you are new to Us2.ai or just curious about what we are building, this is the best place to start.
๐ Book a demo at us2.ai
๐คย ๐๐ฑ๐ฉ๐ฅ๐จ๐ซ๐ ๐จ๐ฎ๐ซ ๐ฉ๐๐ซ๐ญ๐ง๐๐ซ๐ฌ๐ก๐ข๐ฉ๐ฌ!
Did you know Us2.ai is vendor-neutral? We are partnered with leading OEM and device companies, integrated into AI platforms and PACS systems, and supported by distributors across the globe.
Because AI echo shouldn't be locked into one device, one platform or one workflow. It should work wherever clinicians need it.
Explore the full list of partners at the link below.
๐ us2.ai/operations/partnershiโฆ
Do the math โฆ ๐ฆพ๐ซ
โThe AI-ECHO RCT just proved what many suspected.
AI echo doesn't just help. It elevates the echo workflow.
Hear from Dr. Kagiyama on his experience with the Us2.ai software
๐ Full paper: ahajournals.org/doi/10.1161/โฆ
16
1 ๐ข๐ง 4 ๐๐ข๐๐๐๐ญ๐ข๐ ๐ฉ๐๐ญ๐ข๐๐ง๐ญ๐ฌ ๐ก๐๐ ๐ฎ๐ง๐๐ข๐๐ ๐ง๐จ๐ฌ๐๐ ๐ก๐๐๐ซ๐ญ ๐๐๐ข๐ฅ๐ฎ๐ซ๐. ๐๐จ๐ฌ๐ญ ๐ก๐๐ ๐ง๐จ ๐ข๐๐๐. โผ๏ธ
Us2.ai is proud to be a partner in the landmark TARTAN-HF trial which showed that a widely available NT-proBNP blood test, followed by an echo scan, changed everything.
โ
1 in 4 screened patients diagnosed compared to 1% in usual care.
โ
55% reduction in hospitalisation or death.
The evidence is here. Now health systems need to act.
๐ ๐๐๐๐ญ ๐ญ๐ก๐ ๐ญ๐๐๐ฆ ๐๐๐ก๐ข๐ง๐ ๐๐ฌ2.๐๐ข ๐
When you reach out to Us2.ai, these are the people you'll hear from. A small but mighty global sales team, passionate about bringing AI-powered echocardiography to clinicians and institutions around the world.
In the video you'll meet:
๐ย Daniel Ishakย โ Asia-Pacific & Middle East
๐ย Nathan Simcoxย โ Europe
๐ย Seth Koeppelย โ North & South America
And while he couldn't make it on camera this time, rounding out the Americas team is the one and onlyย Dave Ladd.
Whether you're exploring AI echo for the first time or ready to bring Us2.ai into your institution, these are your people.
Don't hesitate to reach out directly or drop a comment below and we'll get you connected.
4 weeks. That's all it took for Bordeaux University Hospital to go fully live with AI echo.
894 echos. 31 parameters. ICC up to 0.97.
Peer-reviewed. GDPR compliant. No VPN. No disruption.
Still hesitating about AI echo? Don't. ๐
๐: us2.ai/clinical-evidence/intโฆ
Stop making measurements manually!
Sonographers face a real physical toll: neck pain, back pain, shoulder strain from scanning and manual measurements all day, when that time and energy could go toward what they were trained for: critical thinking, better imaging, and better patient outcomes.
Us2.ai and Merge built this integration specifically to give that time back.
Here's how it works:
โ
Sonographer scans the patient
โ
Us2.ai's FDA-cleared AI processes the echo in the background
โ
Results appear natively inside Merge Cardio, no extra clicks, no extra logins
โ
By the time the patient is seen out, the measurements are already done
Think of it like CarPlay. The AI runs seamlessly in the background, without changing how clinicians work. No new systems to learn, no extra steps. Just switch it on and the results are already there.
The result? Faster workflows. Healthier echo techs. Better patient care.
๐ฅ Watch the full interview with Cardiac Wire to hear how this works ๐
#ACC26 is a wrap and what a weekend it was! ๐
We are so grateful to our partners @Merative, @viz_ai, and @FujifilmHealth for generously hosting us at their booths throughout the conference. Being able to show our solution live to clinicians on the ground is always a highlight and this year was no exception.
A huge thank you to everyone who stopped by to learn more about what we are building. The conversations, the curiosity, and the enthusiasm from the echo community means everything to us. This is exactly why we do what we do.
The interest in AI-powered echocardiography continues to grow and weekends like this remind us just how much momentum this space has. We are grateful to be part of it.
Missed us this time? Do not fret! We will be on the road again soon. Follow us to be notified the next time we come to a city near you ๐!
Us2.ai's echocardiography AI algorithm will be integrated into a new ATTR-CM care initiative led by @Alnylam in partnership with @viz_ai !
@Alnylam is partnering with @viz_ai, the leader in AI-powered disease detection and care coordination, to develop an AI-enabled ATTR-CM care pathway designed to help clinicians identify patients earlier and guide appropriate diagnostic evaluation and referral.
The pathway combines Us2.ai's FDA-cleared echocardiography AI with EHR connectivity and integration into routine clinical practice to support earlier recognition of ATTR-CM and facilitate coordinated care across cardiology and heart failure teams.
We are proud that our solution will play a role in getting more patients diagnosed earlier, when it matters most.
Read the full press release: investors.alnylam.com/press-โฆ
๐๐ก๐ข๐ฌ ๐ข๐ฌ ๐ฐ๐ก๐๐ญ ๐๐ ๐๐๐ก๐จ ๐๐ง๐๐ฅ๐ฒ๐ฌ๐ข๐ฌ ๐๐๐ญ๐ฎ๐๐ฅ๐ฅ๐ฒ ๐ฅ๐จ๐จ๐ค๐ฌ ๐ฅ๐ข๐ค๐ ๐ฐ๐ข๐ญ๐ก ๐๐ฌ๐.๐๐ข.
What you are seeing:
โ Every view automatically identified and classified
โ Structures traced, measurements calculated
โ Disease detection in real time
โ A full structured report. Ready. Zero clicks.
FDA cleared. CE marked. Running in clinical workflows across the world today.
Curious how our solution could elevate your echo workflow?
๐ Book a demo at us2.ai
New paper in Circulation: Cardiovascular Imaging AI detection of cardiac amyloidosis from a single routine echo view 5,776 patients. UK, Taiwan, US, Japan.
Sensitivity 88.5% | Specificity 87.2% | AUC 0.93
AI deep learning vide-based classifier outperforms the multiparametric score (0.93 vs 0.86, p<0.001).
๐ahajournals.org/doi/10.1161/โฆ
๐ฌ ๐๐โ๐ฏ๐ ๐๐ฅ๐ฐ๐๐ฒ๐ฌ ๐๐๐๐ง ๐ ๐ซ๐จ๐ฎ๐ง๐๐๐ ๐ข๐ง ๐๐ฏ๐ข๐๐๐ง๐๐. ๐๐จ๐ฐ ๐ข๐ญโ๐ฌ ๐๐ฏ๐๐ง ๐๐๐ฌ๐ข๐๐ซ ๐ญ๐จ ๐๐ฑ๐ฉ๐ฅ๐จ๐ซ๐ ๐จ๐ฎ๐ซ๐ฌ.
Our upgraded Clinical Evidence page brings together the validation studies behind our software alongside the growing body of research using Us2.ai in clinical and scientific projects. With new filters across a wide range of topics, thereโs something here for everyone, whether youโre diving into the details or simply looking to satisfy your curiosity.
A big thank you to every researcher and partner who has contributed. This page is for you too!
๐ us2.ai/clinical-evidence/
๐ก We know that bringing new technology into a health system takes more than clinical buy-in.
That's why we've built out dedicated IT & Procurement resources on the new website, everything your technical and procurement teams need to evaluate, plan, and move forward with confidence.
We've tried to make the process as smooth as possible.
Take a look ๐ us2.ai/operations/it-procureโฆ
๐๐โ๐ฏ๐ ๐ฎ๐ฉ๐ ๐ซ๐๐๐๐ ๐ญ๐ก๐ ๐๐ฌ2.๐๐ข ๐ฐ๐๐๐ฌ๐ข๐ญ๐!ย ๐
This is more than a refreshed look. Itโs a milestone that reflects how far weโve come and where weโre headed next.
New pages. New data. New resources. All built to showcase the real-world impact of AI-powered echo analysis.
Weโll be rolling out highlights over the next week, but if you canโt wait, go take a look now ๐
๐: us2.ai
๐ซ ๐๐๐ซ๐๐ข๐๐ ๐๐ฆ๐ฒ๐ฅ๐จ๐ข๐๐จ๐ฌ๐ข๐ฌ ๐ข๐ฌ ๐ฎ๐ง๐๐๐ซ๐๐ข๐๐ ๐ง๐จ๐ฌ๐๐ ๐๐๐, ๐๐ ๐๐๐ง ๐๐ก๐๐ง๐ ๐ ๐ญ๐ก๐๐ญ.
We're proud to share our latest research published in ๐ช๐๐๐๐๐๐๐๐๐๐: ๐ช๐๐๐
๐๐๐๐๐๐๐๐๐๐ ๐ฐ๐๐๐๐๐๐: The development and external validation of Us2's deep learning model for automated detection of cardiac amyloidosis (CA) on echocardiography.
Trained on 4,371 patients across the UK and Taiwan, and externally validated in the US and Japan across 5,776 patients in total, the results speak for themselves:
โก๏ธ AUC 0.93 | 88.5% sensitivity | 87.2% specificity
โก๏ธ Robust performance across age, sex, race, amyloid subtype and echo vendor
โก๏ธ Consistently differentiates CA from other hypertrophic phenotypes including HCM, aortic stenosis, hypertension and CKD
โก๏ธ Full report generated in 68 ๐ฌ๐๐๐จ๐ง๐๐ฌ
Huge thanks to our collaborators at the National Amyloidosis Centre (UCL), Duke University Health System, National Cerebral and Cardiovascular Center (Japan), and MacKay Memorial Hospital (Taiwan).
๐ Read the full paper: us2.ai/clinical-evidence/diaโฆ
๐ฉ Contact us to learn more!
๐ฃ๏ธ
๐ ๐ง๐๐ฐ #JACC ๐๐ก๐ข๐ฌ ๐๐๐๐ค ๐๐ฉ๐ข๐ฌ๐จ๐๐ ๐ก๐๐ฌ ๐ฃ๐ฎ๐ฌ๐ญ ๐๐ซ๐จ๐ฉ๐ฉ๐๐! Co-hosted by our co-founder @lamcardio this episode focuses on Cardiac Amyloidosis...
490 ๐๐๐ฒ๐ฌ.
That is the median delay to diagnosis reported in recent data.
At the same time, mortality benefit in ATTR-CM trials emerges within 12โ18 months.
The field is moving from
๐ช๐๐ ๐๐ ๐
๐๐๐๐๐๐๐ ๐๐๐๐
๐๐๐ ๐๐๐๐๐๐๐
๐๐๐๐?
to
๐ฏ๐๐ ๐
๐ ๐๐ ๐
๐๐๐๐๐๐๐ ๐๐๐๐๐๐๐, ๐๐๐
๐๐๐๐๐๐๐๐๐๐๐๐๐๐?
At Us2.ai, this is exactly the problem we are building for.
๐๐ฎ๐ซ ๐๐ ๐๐๐ก๐จ๐๐๐ซ๐๐ข๐จ๐ ๐ซ๐๐ฉ๐ก๐ฒ ๐ฉ๐ฅ๐๐ญ๐๐จ๐ซ๐ฆ ๐ข๐ฌ ๐ญ๐ก๐ ๐๐ข๐ซ๐ฌ๐ญ ๐๐ง๐ ๐จ๐ง๐ฅ๐ฒ ๐ฉ๐ฅ๐๐ญ๐๐จ๐ซ๐ฆ ๐ญ๐ก๐๐ญ ๐ฌ๐ฎ๐ฉ๐ฉ๐จ๐ซ๐ญ๐ฌ ๐๐๐ซ๐๐ข๐๐ ๐๐ฆ๐ฒ๐ฅ๐จ๐ข๐๐จ๐ฌ๐ข๐ฌ ๐๐๐ญ๐๐๐ญ๐ข๐จ๐ง ๐ญ๐ก๐ซ๐จ๐ฎ๐ ๐ก ๐๐๐๐:
โก๏ธ Automated, guideline-based chamber quantification and measurements
โก๏ธ AI-driven pattern recognition
By combining standardized measurements with disease-pattern analysis, AI can help surface high-risk patients earlier.
When disease is progressive and increasingly treatable, systematic detection matters.
๐๏ธ Listen to the full podcast discussion!
New #JACC This Week is live ๐ง
Drs. Harlan Krumholz @hmkyale & Carolyn Lam @lamcardio dive into this week's issue on cardiac #amyloidosis, one of the fastest-moving areas in cardiology.
Bottom line: earlier diagnosis & treatment save lives.
Listen ๐ podcasts.apple.com/us/podcasโฆ
Bye bye to โRV; the forgotten chamberโ, hello to automation making us better! Big win for patients with #pulmonaryHT
๐๐๐ง ๐
๐ฎ๐ฅ๐ฅ๐ฒ ๐๐ฎ๐ญ๐จ๐ฆ๐๐ญ๐๐ ๐๐ ๐๐๐ก๐จ ๐๐ฎ๐ฉ๐ฉ๐จ๐ซ๐ญ ๐๐ฎ๐ฅ๐ฆ๐จ๐ง๐๐ซ๐ฒ ๐๐ฒ๐ฉ๐๐ซ๐ญ๐๐ง๐ฌ๐ข๐จ๐ง ๐๐ฌ๐ฌ๐๐ฌ๐ฌ๐ฆ๐๐ง๐ญ?
A new study published in CHEST journal shows thatย Us2.aiโs fully automated AI softwareย can reliably assess PH, providingย ๐๐๐ฌ๐ญ๐๐ซ ๐๐ง๐ ๐ฆ๐จ๐ซ๐ ๐๐จ๐ง๐ฌ๐ข๐ฌ๐ญ๐๐ง๐ญ ๐ฆ๐๐๐ฌ๐ฎ๐ซ๐๐ฆ๐๐ง๐ญ๐ฌ.
The AI was tested against expert cardiology readings and showedย ๐ฆ๐ข๐ง๐ข๐ฆ๐๐ฅ ๐๐ข๐๐๐๐ซ๐๐ง๐๐๐ฌ in key echo measurements, including peak tricuspid regurgitation velocity (TRV), right atrial area, and tricuspid annular plane systolic excursion.
โผ๏ธ Importantly, the AIย ๐๐๐๐ฎ๐ซ๐๐ญ๐๐ฅ๐ฒ ๐๐๐ญ๐๐๐ญ๐๐ ๐๐, with performance comparable to human experts.
These results suggest thatย Us2.ai can:
โ
๐ฌ๐ญ๐ซ๐๐๐ฆ๐ฅ๐ข๐ง๐ ๐๐ ๐๐ฌ๐ฌ๐๐ฌ๐ฌ๐ฆ๐๐ง๐ญ
โ
๐ซ๐๐๐ฎ๐๐ ๐ฆ๐๐ง๐ฎ๐๐ฅ ๐ฐ๐จ๐ซ๐ค๐ฅ๐จ๐๐
โ
๐ฌ๐ฎ๐ฉ๐ฉ๐จ๐ซ๐ญ ๐ฆ๐จ๐ซ๐ ๐๐๐๐ข๐๐ข๐๐ง๐ญ ๐๐ฅ๐ข๐ง๐ข๐๐๐ฅ ๐๐๐๐ข๐ฌ๐ข๐จ๐ง-๐ฆ๐๐ค๐ข๐ง๐
๐ Read the full study here: us2.ai/publications/advancinโฆ
6


















